Atopic Dermatitis Archives - Medical Conferences

3-Year results highlight durable effects of IL-13 inhibitor in AD

Presented By

Prof. Diamant Thaçi, University of Lübeck, Germany

Trial

ADjoin

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:59

IL-22RA1 inhibition shows potential in atopic dermatitis

Presented By

Dr Christine Bangert, Medical University Vienna, Austria

Trial

Phase 2

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:56

Lifelong psychosocial burden linked to early-onset atopic dermatitis

Editor

George Washington University School of Medicine, USA

Trial

Scars of Life

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:53

Second-generation selective PDE4 inhibitor shows promise in AD

Presented By

Prof. Eric Simpson, Oregon Health and Science University, USA)

Trial

Phase 2, ADESOS

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:50

Delgocitinib cream outperforms oral alitretinoin in chronic hand eczema

Presented By

Prof. Ana Giménez-Arnau, Autonomous University of Barcelona, Spain

Trial

Phase 3, DELTA FORCE

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:33

Atopic hand eczema: similar treatment success for dupilumab and topical delgocitinib

Presented By

Prof. April Armstrong, University of California Los Angeles, USA

Trial

DELTA; LIBERTY-AD-HAFT

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:30

What’s new in clinical dermatology?

Presented By

Dr Tamar Nijsten, Erasmus University Medical Centre, the Netherlands

Conference

DDD 2024

Type

Peer-reviewed article

31 May 2024 13:31

Children with atopic dermatitis may be smaller and heavier than healthy children

Presented By

Prof. Amy Paller, Northwestern University‘s Feinberg School of Medicine, USA

Trial

PEDISTAD

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 16:54

Amlitelimab leads to a high response 28 weeks after treatment discontinuation

Presented By

Prof. Stephan Weidinger, Christian-Albrechts-University Kiel, Germany

Trial

Phase 2, STREAM-AD

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 15:35

Delgocitinib cream: A promising treatment option for chronic hand eczema

Presented By

Prof. Melinda Gooderham, Queens University, Canada

Trial

Phase 3, DELTA 3

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 15:31

Tapinarof on course to become a new topical treatment in AD

Presented By

Dr Jonathan Silverberg, George Washington University, USA

Trial

Phase 3, ADORING

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 13:43

Upadacitinib provides sustained skin clearance in adolescents and adults with AD

Presented By

Dr Jonathan Silverberg, George Washington University, USA

Trial

Phase 3, Measure Up; AD UP

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 13:39

Sustained deep clinical and itch responses with novel IL-13 inhibitor

Presented By

Prof. Eric Simpson, Oregon Health & Science University, USA

Trial

Phase 3, ADvocate; ADvantage

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 13:13

Encouraging results for amlitelimab in atopic dermatitis

Presented By

Prof. Stephan Weidinger, University Hospital Schleswig-Holstein, Germany

Trial

Phase 2, STREAM-AD

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 13:03

Chronic hand eczema: patients share similar molecular signatures regardless of AD status

Presented By

Dr Jonathan Bar, Icahn School of Medicine at Mount Sinai, USA

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 12:58

Severe hand eczema: dupilumab could be a future treatment

Presented By

Dr Laura Loman, University Medical Center Groningen, the Netherlands

Trial

Phase 2

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 12:55

Rocatinlimab delivers efficacy and safety in atopic dermatitis

Presented By

Prof. Emma Guttman-Yassky, Icahn School of Medicine at Mount Sinai, NY, USA

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 18:08

Head-to-head: paraffin- versus ceramide-based moisturiser for paediatric AD

Presented By

Prof. Sachin Gupta, All India Institute of Medical Sciences, India

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 18:06

JAK inhibitors for AD in the real world

Presented By

Dr Yik Weng, National Skin Centre, Singapore

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 18:02

Novel JAK1 inhibitor for patients with atopic dermatitis

Presented By

Jianzhong Zhang, Peking University People’s Hospital, China

Trial

Phase 3, QUARTZ3

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 18:00

Can lebrikizumab maintain response rates in atopic dermatitis?

Presented By

Prof. Emma Guttman-Yassky, Icahn School of Medicine at Mount Sinai, NY, USA

Trial

Phase 3, ADvocate 1 and ADvocate 2

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 17:58

Most patients with AD on dupilumab stick with this drug long-term

Presented By

Dr Elena Pezzolo, San Bortolo Hospital, Italy

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 17:56

Dupilumab: a viable option for atopic hand and foot eczema

Presented By

Prof. Eric Simpson, Oregon Health & Science University, OR, USA

Trial

Phase 3, LIBERTY-AD-HAFT

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 11:33

Topical roflumilast beneficial in atopic dermatitis

Presented By

Prof. Lawrence Eichenfield, University of California San Diego, CA, USA

Trial

Phase 3, INTEGUMENT-1 and INTEGUMENT-2

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 11:27

IL-22 receptor blocker reduces itch and skin lesions in AD

Presented By

Prof. Diamant Thaçi, University of Lübeck, Germany

Trial

Phase 2

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 11:17

Delgocitinib shows promise as topical therapy for chronic hand eczema

Presented By

Dr Robert Bissonnette, Innovaderm Research, Canada

Trial

Phase 3, DELTA 1

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 10:58

Eligibility and selection of JAK inhibitors for constitutional eczema

Presented By

Dr Dirk Jan Hijnen, Erasmus MC, the Netherlands

Conference

DDD 2023

Type

Peer-reviewed article

10 May 2023 13:57

Baricitinib possible therapeutic option for children with AD

Presented By

Dr Antonio Torrelo Fernández, Hospital Infantil Universitario Niño Jesús, Spain

Trial

Phase 3, BREEZE-AD-PEDS

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 09:15

Amlitelimab therapy leads to sustained decrease of IL-22 in AD patients

Presented By

Dr Stephan Weidinger, University Hospital Schleswig-Holstein, Germany

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 09:10

IL-13 inhibition with lebrikizumab shows high maintenance rates in AD

Presented By

Prof. Andrew Blauvelt, Oregon Medical Research Center, OR, USA

Trial

Phase 3, ADvocate

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 09:05

Does 8 weeks of emollients use prevent AD in high-risk infants?

Presented By

Prof. Alan Irvine, Trinity College Dublin, Ireland

Trial

STOP AD

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 09:02

Therapies for atopic dermatitis: still moving forward

Presented By

Prof. Christian Vestergaard, Aarhus University Hospital, Denmark

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:58

Children with AD: high risk of bacterial infections in carriers of a filaggrin gene variant

Presented By

Prof. Alina Suru , Carol Davila University of Medicine and Pharmacy, Romania

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:53

No adverse pregnancy outcomes in patients exposed to baricitinib

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:47

AD treatment during the pandemic: dupilumab does not raise COVID-19 infection risk

Presented By

Dr Brian Rankin, University of Calgary, Canada

Trial

Cohort study

Conference

AAD 2022

Type

Peer-reviewed article

18 May 2022 12:27

Upadacitinib: Fast and more pronounced skin improvement in AD patients

Presented By

Prof. Jonathan Silverberg, George Washington University School of Medicine, USA

Trial

Phase 3, Heads Up

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 12:35

Lebrikizumab treatment leads to encouraging outcomes in multiple traits of AD

Presented By

Prof. Jonathan Silverberg, George Washington University School of Medicine, USA

Trial

Phase 3, ADvocate 1; ADvocate 2

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 12:18

Novel IL-4/IL-13 blocker shows high efficacy with only modest conjunctivitis signal

Presented By

Prof. Andrew Blauvelt, Oregon Medical Research Center, USA

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 12:15

JAK inhibitors: A risk assessment

Presented By

Prof. Brett King, Yale School of Medicine, USA

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 10:59

Monitoring is key during JAK inhibitor therapy

Presented By

Prof. Jonathan Silverberg

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 10:47

AAD 2022 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

AAD 2022

14 April 2022 11:02

Ceramides and their role in skincare

Presented By

Prof. John Su; Dr Katherine Armour

Conference

ICD 2021

Type

News article

2 December 2021 16:47

Targeting OX40 in the treatment of atopic dermatitis meets expectations

Presented By

Prof. Stephan Weidinger, University Hospital Schleswig-Holstein, Germany

Trial

Phase 2

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:35

Superior EASI scores after switch from dupilumab to upadacitinib

Presented By

Prof. Andrew Blauvelt, Oregon Medical Research Center, USA

Trial

Heads Up

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:34

Long-term disease control in AD could be in reach with anti-OX40 antibody KHK4083

Presented By

Prof. Emma Guttman-Yassky, Icahn School of Medicine at Mount Sinai, USA

Trial

Phase 2

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:28

Abrocitinib demonstrates fast itch control and skin clearance in atopic dermatitis

Presented By

Prof. Kristian Reich, University Medical Center Hamburg-Eppendorf, Germany

Trial

Phase 3, JADE DARE

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:26

AD patients with stable response fare well with a monthly dose of tralokinumab

Presented By

Prof. Stephan Weidinger, University of Kiel, Germany

Trial

ECZTRA1 and 2

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:25

Upadacitinib beats dupilumab in different body regions

Presented By

Prof. Jacob Thyssen, Bispebjerg Hospital, Denmark

Trial

Phase 3, Heads Up

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:23

Efficacious 2-year AD control with IL-13 inhibitor tralokinumab

Presented By

Prof. Andrew Blauvelt, Oregon Medical Research Center, USA

Trial

ECZTEND

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:22

Ruxolitinib cream: a safe treatment for elderly AD patients

Presented By

Prof. Jacek Szepietowksi, Wroclaw Medical University, Poland

Trial

Phase 3, TRuE-AD1; TRuE-AD2

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:21

Novel and upcoming targeted AD treatment

Presented By

Prof. Emma Guttman-Yassky, Icahn School of Medicine at Mount Sinai, USA

Trial

ECZTRA 3; Measure Up; ADVISE

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:20

Opioid receptor agonist difelikefalin disappoints in AD

Presented By

Prof. Brian Kim, Washington University School of Medicine, USA

Trial

Phase 2, KARE

Conference

EADV 2021

Type

Peer-reviewed article

17 November 2021 14:28

EADV 2021 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Trial

PSOARING 3, JADE-DARE, HEADS UP

Conference

EADV 2021

19 October 2021 00:08

Comorbidity is common in adult and paediatric atopic dermatitis patients

Presented By

Prof. Jonathan Silverberg, George Washington University, WA, USA

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:30

Atopic dermatitis in children has a severe impact on their families

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:05

Meaningful amelioration of quality of life in paediatric AD patients on dupilumab

Trial

Phase 3, LIBERTY AD PEDS

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:00

Meaningful sleep improvement with IL-13 inhibition

Presented By

Prof. Jonathan Silverberg, George Washington University, USA

Trial

Phase 3, ECZTRA

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 14:33

Baricitinib in AD: Efficacy paired with consistent long-term results

Presented By

Prof. Jonathan Silverberg , George Washington University, USA

Trial

Phase 3, BREEZE-AD3

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 14:31

Topical JAK inhibition: a novel treatment option for patients with mild-to-moderate AD

Presented By

Prof. Megan Landis, University of Louisville School of Medicine, USA

Trial

Phase 2

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 14:22

Light at the end of the tunnel for chronic hand eczema

Presented By

Prof. Margitta Worm, Prof. Howard Sofen

Trial

Phase 2

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 13:37

Oral JAK 1 inhibitor leads to fast itch relieve and remarkable skin clearance in AD

Presented By

Prof. Emma Guttman-Yassky, Icahn School of Medicine at Mount Sinai, USA

Trial

Phase 3, Measure Up

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 13:24

Effects IL-13 blocker improves with longer treatment duration

Presented By

Prof. Eric Simpson, Oregon Health & Science University, USA

Trial

Phase 3, ECZTRA

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 12:37

Baricitinib beneficial in head and neck AD

Presented By

Dr Eric Simpson, Oregon Health and Science University, USA

Trial

Phase 3, BREEZE-AD1 and BREEZE-AD2

Conference

AAD 2020

Type

Peer-reviewed article

19 August 2020 07:23

Cannabinoids: a future role in dermatology?

Presented By

Prof. Adam Friedman, School of Medicine & Health Sciences, USA

Conference

AAD 2020

Type

Peer-reviewed article

6 August 2020 09:01

Good response and pruritus reduction in AD with novel selective JAK1 inhibitor

Presented By

Dr Melinda Gooderham

Trial

JADE MONO-2

Conference

AAD 2020

Type

Peer-reviewed article

6 August 2020 07:08

IL-13 blocker tralokinumab effective in AD

Presented By

Prof. Eric Simpson

Trial

ECZTRA

Conference

AAD 2020

Type

Peer-reviewed article

6 August 2020 07:06

Tape stripping – a painless way to distinguish AD and psoriasis?

Presented By

Dr Robert Bissonnette, Innovaderm Research, Canada

Conference

AAD 2020

Type

Peer-reviewed article

6 August 2020 07:05

IL-4/IL-13 blocker dupilumab effective in children with severe AD

Presented By

Prof. Amy S. Paller, Northwestern University Feinberg School of Medicine, USA

Trial

Phase 3, LIBERTY AD PEDS

Conference

AAD 2020

6 August 2020 07:04

Better compliance in AD skin care with novel emollient stick

Conference

AAD 2020

Type

Peer-reviewed article

6 August 2020 06:37

Small molecules: interesting novel treatment options in AD

Presented By

Prof. Tilo Biedermann, Helmholtz Center Munich, German

Conference

EADV 2019

Type

Peer-reviewed article

9 December 2019 20:27

IL-1⍺ blockade: a new treatment option in AD

Presented By

Prof. Alice Gottlieb, Icahn School of Medicine at Mount Sinai, USA

Conference

EADV 2019

Type

Peer-reviewed article

9 December 2019 19:51

IL-4/IL-13 blockade leads to rapid itch reduction in adolescents

Presented By

Prof. Eric Simpson, Oregon Health & Science University, USA

Trial

Phase 3, LIBERTY AD ADOL

Conference

EADV 2019

Type

Peer-reviewed article

9 December 2019 18:58

JAK inhibition plus TCS lead to high clearance rates in AD

Presented By

Prof. Kristian Reich, Georg-August-University Göttingen, Germany

Trial

Phase 3, BREEZE-AD7

Type

Peer-reviewed article

9 December 2019 16:53

How to manage conjunctivitis in AD patients treated with a biologic

Presented By

Prof. Tilo Biedermann, Helmholtz Center Munich, Germany

Conference

EADV 2019

Type

Peer-reviewed article

9 December 2019 16:01

Biologics: increasingly used in paediatric dermatology

Presented By

Prof. Marieke Seyger, Radboud University Nijmegen, the Netherlands

Conference

EADV 2019

Type

Peer-reviewed article

9 December 2019 15:16

No cancer risk with long-term use of tacrolimus, a topical calcineurin inhibitor, in children with AD

Presented By

Prof. Regina Fölster-Holst, University Medical Center Schleswig-Holstein, Germany

Trial

APPLES

Conference

EADV 2019

Type

Peer-reviewed article

9 December 2019 15:04

Green light for a second JAK inhibitor in AD

Presented By

Prof. Eric Simpson, Oregon Health & Science University, USA

Trial

Phase 3, JADE MONO-1

Conference

EADV 2019

Type

Peer-reviewed article

9 December 2019 14:06

Comorbidities more common in chronic urticaria, psoriasis, and AD

Presented By

Dr Karsten Weller, Charité University Hospital, Germany

Conference

EADV 2019

Type

Peer-reviewed article

9 October 2019 20:40

Reduced sleep quality in dermatoses influenced by itch and pain

Presented By

Dr Karolina Kaaz, Wroclaw Medical University, Poland

Conference

EADV 2019

Type

Peer-reviewed article

9 October 2019 19:58

Anxiety and depression are common in families of AD infants

Presented By

Dr Vesna Grivcheva-Panovska, University Clinic in Skopje (Macedonia)

Conference

EADV 2019

Type

Peer-reviewed article

9 October 2019 18:59

Statin use elevates risk of eczema and atopic dermatitis

Conference

WCD 2019

Type

Peer-reviewed article

26 August 2019 20:50

Insights into pathogenesis of AD define novel therapeutic targets

Presented By

Prof. Graham Ogg & Prof. Emma Guttman-Yassky

Conference

WCD 2019

Type

Peer-reviewed article

26 August 2019 20:29

Long awaited oral therapy for moderate-to-severe AD

Presented By

Prof. Thomas Bieber, University Medical Center Bonn, Germany

Conference

WCD 2019

Type

Peer-reviewed article

26 August 2019 19:14

Combinations are hot in AD treatment

Presented By

Dr Magdalena Trzeciak, Medical University of Gdansk, Poland

Trial

LIBERTY AD CHRONOS

Conference

WCD 2019

Type

Peer-reviewed article

26 August 2019 10:34

Understanding genetics to unravel psoriasis and atopic dermatitis pathogenesis

Presented By

Prof. Jonathan Barker, Kings College London, United Kingdom

Conference

SPIN 2019

Type

Peer-reviewed article

21 June 2019 20:34

Fumarates and vitamin A derivatives advance and latest insights in non-biologic systemic therapeutic agents in psoriasis and atopic dermatitis

Presented By

Prof. Peter van de Kerkhof, Radboud University Medical Center, the Netherlands

Conference

SPIN 2019

Type

Peer-reviewed article

21 June 2019 18:02

Reduction in coronary artery disease in psoriasis patients treated with biologic therapies, possible implications for atopic dermatitis

Presented By

Dr Nehal Mehta; Prof. Emma Guttman-Yassky

Trial

NHANES

Conference

SPIN 2019

Type

Peer-reviewed article

21 June 2019 14:38

Atopic dermatitis and psoriasis: on a spectrum?

Presented By

Prof. Emma Guttman-Yassky, Mount Sinai Medical School, USA

Conference

SPIN 2019

Type

Peer-reviewed article

21 June 2019 13:39

Bermekimab – a future treatment for atopic dermatitis?

Presented By

Prof. Eric Simpson, Oregon Health & Science University, USA

Conference

AAD 2019

Type

Peer-reviewed article

19 April 2019 22:17

New and emerging atopic dermatitis therapies

Presented By

Prof. David Cohen, New York University School of Medicine, USA

Conference

AAD 2019

Type

Peer-reviewed article

19 April 2019 20:43

Tralokinumab improves eczema and reduces staphylococcus aureus colonisation in AD

Conference

AAD 2019

Type

Peer-reviewed article

19 April 2019 18:14

Can JAK inhibitors close the current therapeutic gap in AD?

Presented By

Prof. Eric Simpson, Oregon Health & Science University, USA

Conference

AAD 2019

Type

Peer-reviewed article

19 April 2019 14:12

Food triggers eczema – an imperturbable belief of patients

Presented By

Dr Peter Lio, Northwestern University Chicago, USA

Conference

AAD 2019

Type

Peer-reviewed article

19 April 2019 13:45

AD sleep disturbance, antihistamines and osteoporosis

Presented By

Prof. Jonathan Silverberg, Northwestern University’s Feinberg School of Medicine, USA

Conference

AAD 2018

Type

Peer-reviewed article

20 December 2018 18:36

IL-17C inhibition in AD and new oral treatments

Presented By

Prof. Diamant Thaçi, University Clinic Schleswig-Holstein, Germany; Prof. Emma Guttmann-Yassky, Mount Sinai Hospital, USA

Conference

AAD 2018

Type

Peer-reviewed article

20 December 2018 17:20

New topical and systematic treatments

Presented By

Prof. Eric Simpson, Oregon Health & Science University, USA

Conference

AAD 2018

Type

Peer-reviewed article

20 December 2018 16:42

Dual JAK/SYK inhibitor and anti-IL-33 blockade

Presented By

Dr Robert Bissonnette, Innovaderm Research, Canada; Prof. Graham Ogg, Oxford University, United Kingdom

Conference

AAD 2018

Type

Peer-reviewed article

20 December 2018 16:25

IL-4/IL-13 inhibition

Presented By

Prof. Eric Simpson, Oregon Health & Science University, USA

Trial

SOLO

Conference

AAD 2018

Type

Peer-reviewed article

20 December 2018 11:49

[Long Read] Current Look on Asthma

Presented By

Prof. Zuzana Diamant, Skåne University Hospital Lund, Sweden; University Medical Center Groningen, the Netherlands

Trial

COSMEX, COSMOS, BORA

Conference

ERS 2018

Type

Peer-reviewed article

7 November 2018 23:25